2019 BioHealth Capital Region Forum

Top 3 by 2023

Miss the 2019 BioHealth Capital Region Forum?

 

20% of the top influencers worldwide in vaccine development

 

World-class tech + big data + biotech + White House Precision Medicine Initiative = new frontiers in patient-centered medicine

1
1

MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

  • World–renowned research institutions and universities
  • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
  • Fastest growing region for healthcare companies in the U.S.
  • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

Founding Partners

AstraZeneca, Learning Undefeated and Discovery Education Launch New Generation Health Program to Encourage Healthy Living Through Science-Based Learning

September 12, 2019

New STEM Program Inspires Middle School Students to Connect Science and Healthy Living Through Experiential Learning Resources Silver Spring, Md., Sep. 12 /CSRwire/ –  AstraZeneca, Learning Undefeated and Discovery Education, the leading provider…

Kinexum’s Dr. Zan Fleming, M.D. and Thomas Seoh join Rich Bendis on BioTalk

September 10, 2019

Dr. Zan Fleming, M.D. and Thomas Seoh of Kinexum join Biotalk host Rich Bendis to discuss the company, Metabesity, and their upcoming 2019 Conference in Washington, DC Listen now on…

Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder

September 6, 2019

GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a…

Regenxbio, Clearside enter option and license agreement for SCS Microinjector

September 6, 2019

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space….

Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

September 3, 2019

Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weapon Supports the government’s continued efforts and long-term strategy to maintain…

WBJ: Viela Bio files to go public with $150M offering

August 30, 2019

Gaithersburg-based Viela Bio Inc. has filed to begin trading publicly with a $150 million initial public offering, fast bringing the business full circle after its spinout from MedImmune in early…